NIMGenetics introduces Colotect, a non-invasive test for the early detection of colorectal cancer (CRC) and precancerous lesions, based on the methylation status of the SDC2, PPP2R5C and ADHFE1 genes in stool DNA.
Data from the last two decades have unequivocally illustrated that epigenetic marks are important molecular hallmarks of cancer, as they occur very early in disease pathogenesis, involve virtually all key pathways associated with cancer, and most importantly , can be exploited as biomarkers of clinically relevant diseases.
The median 5-year survival rate for early-stage RCC can be as high as 90%. However, it may be less than 10% in patients with metastatic disease. Therefore, early detection of CRC has become a key global problem to reduce its high mortality.
The high sensitivity of Colotect, superior to that of the fecal occult blood test for the detection of colorectal cancer, is maintained in the different stages of CRC and can be up to 50% higher than that of the fecal occult blood test in the case of of precancerous lesions. Colotect brings greater peace of mind to patients, thanks to a low false negative rate.
Colotect is a test that is carried out on a stool sample; It is simple, painless and non-invasive. It is marketed as a service provided from our laboratory located in Spain, or as a kit to be internalized in our own laboratories.
Turnaround time: 20 days.
Diagnostic service reference: COL1001
Colotect sample collection kit reference: PCOLCK.1SS
Colotect reagent kit reference (50 tests): BGPRTA-001
